0000950170-24-008046.txt : 20240126
0000950170-24-008046.hdr.sgml : 20240126
20240126190645
ACCESSION NUMBER: 0000950170-24-008046
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240124
FILED AS OF DATE: 20240126
DATE AS OF CHANGE: 20240126
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schor Chen
CENTRAL INDEX KEY: 0001340875
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38359
FILM NUMBER: 24569651
MAIL ADDRESS:
STREET 1: PREDIX PHARMACEUTICALS HOLDINGS, INC.
STREET 2: 4 MAGUIRE ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adicet Bio, Inc.
CENTRAL INDEX KEY: 0001720580
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 813305277
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 BERKELEY STREET
STREET 2: 19TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 617-482-2333
MAIL ADDRESS:
STREET 1: 200 BERKELEY STREET
STREET 2: 19TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
FORMER COMPANY:
FORMER CONFORMED NAME: resTORbio, Inc.
DATE OF NAME CHANGE: 20171024
4
1
ownership.xml
4
X0508
4
2024-01-24
0001720580
Adicet Bio, Inc.
ACET
0001340875
Schor Chen
C/O ADICET BIO, INC.
200 BERKELEY STREET, 19TH FLOOR
BOSTON
MA
02116
true
true
false
false
President & CEO
false
Common Stock
2024-01-24
4
F
false
15290
2.40
D
138471
D
Common Stock
2024-01-24
4
A
false
70300
0.00
A
208771
D
Common Stock
43469
I
See Footnote
Common Stock
53424
I
See Footnote
Stock Option (Right to Buy)
2.40
2024-01-24
4
A
false
1116903
0.00
A
2034-01-23
Common Stock
1116903
1116903
D
Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.
The Reporting Person was issued RSUs. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in three (3) annual installments, with the first tranche vesting on January 24, 2025. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.
Represents shares held directly by The I. Schor IRRV Trust, an irrevocable family trust having an independent trustee.
Represents shares held directly by The C. Schor IRRV Trust, an irrevocable family trust having an independent trustee.
1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.
/s/ Nick Harvey, Attorney-in-Fact
2024-01-26